Tevogen (TVGN) Current Assets (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Current Assets came in at $2.1 million in Q1 2026, down 30.44% YoY from $3.1 million in Q1 2025, and up 39.05% on a QoQ basis from $1.5 million in Q4 2025.
Tevogen (TVGN) Current Assets (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Current Assets data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Current Assets fell 30.44% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 30.44% YoY) and the FY2025 annual result came in at $1.5 million, down 34.78% from the prior year.
- Current Assets improved to $2.1 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $3.5 million in Q3 2024 to a low of $97064.0 in Q1 2023.
- A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets slumped 86.78% — and 2024, when it soared 2372.51%.
- Tracing TVGN's Current Assets over 5 years: stood at $274356.0 in 2022, then soared by 528.01% to $1.7 million in 2023, then surged by 37.02% to $2.4 million in 2024, then slumped by 34.78% to $1.5 million in 2025, then surged by 39.05% to $2.1 million in 2026.
- The last three Current Assets figures came in at $2.1 million (Q1 2026), $1.5 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 1.76 Bn |
| 10 | Tevogen | 26.21 Mn | 26.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 2.36 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 399,474.00 |
| Jun 30, 2023 | 699,327.00 |
| Mar 31, 2023 | 97,064.00 |
| Dec 31, 2022 | 274,356.00 |
| Sep 30, 2022 | 418,473.00 |
| Jun 30, 2022 | 594,755.00 |
| Mar 31, 2022 | 734,159.00 |
| Dec 31, 2021 | 791,191.00 |